Navigation Links
CPA Acquires Renowned German Patent Research Specialist, SVPG
Date:10/8/2008

LONDON, October 8 /PRNewswire/ --

- Strengthens Expertise in Key Market and Industry Sectors, Including Pharmaceutical and Chemical

CPA, the world's top intellectual-property management specialist and a leading provider of outsourced legal support services, announced today that it has acquired renowned German patent research firm SVPG GmbH. Frankfurt-based SVPG, formerly part of Hoechst AG, has a proud history in patent research dating back more than 20 years and specialising in the pharmaceutical, chemical, life sciences, biotech, and engineering sectors.

The acquisition underlines CPA's commitment to become the leading player in the global patent research business by increasing its presence in key international markets and further strengthening its expertise in specialist industry sectors. CPA is already one of the largest patent researching entities in the world, with offices in the UK (London), Germany (Munich), the US (Alexandria, VA) and India (Noida), and more than 90 patent research specialists located across three continents.

Chris Veator, Executive Vice-President, CPA Legal Services, said: "We are continuing to expand our portfolio of patent lifecycle services, of which Patent Research is a critical component. Patent research is an area of strong growth in the outsourced legal services (http://www.cpaglobal.com/legal_process_outsourcing) industry, especially for CPA, and the acquisition of SVPG is a significant part of our growth strategy. It will make an important contribution towards our goal of becoming the recognised global leader in quality patent research for all our clients."

Randy Lacasse, Head of CPA's patent search business, said: "We're delighted to be bringing SVPG into our global patent research business. They are a highly respected firm with first rate patent research and technical analysis skills. The acquisition strengthens our presence and client base in the important German market, while further enhancing our expertise in key industry sectors such as pharmaceutical, chemical and life sciences, as well as our linguistic capabilities."

About SVPG

Formerly a business unit of German chemical and life sciences company Hoechst AG (now part of Sanofi Aventis), SVPG has a proud history in patent research dating back more than 20 years and specialising in the chemical, life sciences, pharmaceutical, biotech, and engineering sectors. SVPG counts amongst its clients many of the leading corporations and law firms in Germany.

For further information visit: http://www.svpg.de/en

About CPA

With clients in over 100 countries, CPA is a leading provider of outsourced legal support services and the world's top intellectual property (IP) management specialist. Founded in 1969, CPA provides lifecycle management services for intellectual property (http://www.cpaglobal.com) such as patent, design and trademark searching, watching, renewals, and portfolio strategy. CPA is also a leader in the growing market for outsourced contract management (http://www.cpaglobal.com/legal_process_outsourcing/contract_management) and litigation support services, helping law firms and corporations to realise value by managing risk, cost and capacity. CPA employs over 1,000 people in 16 offices in 8 countries.

For further information visit: http://www.cpaglobal.com

CPA and Patent Research

The value and critical nature of patents in business has become far more important and apparent in recent years, with patents underpinning a high proportion of corporate valuations through "intangible assets" and with increased emphasis on patent commercialisation, such as active patent portfolio strategy management, licensing, and divesting non-core assets. As a result, maintenance of existing portfolios, applications for new patents (http://www.cpaglobal.com/patents) and the rise of patent litigation are increasingly complicated, time consuming and costly. Patent research is a fundamental step in the process of filing patent applications, managing a patent portfolio and supporting patent litigation, which make it a key driver behind the Intellectual Property strategy (http://www.cpaglobal.com/ip-review-online/ip-strategy) of many businesses today. Now in its 15th year of patent research, CPA has conducted over 25,000 patent search projects and is one of the largest patent researching entities in the world, with more than 100 patent research specialists located across three continents able to consistently deliver high quality patent searches (http://www.cpaglobal.com/patents/research), quickly and methodically. CPA provides a full range of patent research services including Patentability/Novelty searches in support of new inventions, Freedom to Operate searches in connection with new product launches, advanced Patent Landscaping to assist strategic patent portfolio management ( http://www.cpaglobal.com/trademarks) and Validity or Clearance/Infringement searches related to patent litigation.

For further information visit: http://www.cpaglobal.com/patents

Related links:

http://www.cpaglobal.com

http://www.cpaglobal.com/patents/research

http://www.cpaglobal.com/patents

http://www.cpaglobal.com/legal_process_outsourcing

http://www.cpaglobal.com/trademarks

http://www.cpaglobal.com/legal_process_outsourcing/contract_management

http://www.cpaglobal.com/ip-review-online/ip-strategy

Media Contacts

UK

Steve Clark

CPA

+44(0)1784-224-351

sclark@cpaglobal.com

Kate Miller

Brunswick Group

+44(0)20-7404-5959

cpauk@brunswickgroup.com

USA

Julie Mandell

CPA

+1-571-227-7025

jmandell@cpaglobal.com

Justin Dini

Brunswick Group

+1-212-333-3810

cpaUS@brunswickgroup.com


'/>"/>
SOURCE CPA
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Circassia Acquires North American and Japanese Rights to Dopexamine
2. Advanced Instruments Acquires D & F Control Systems Inc.
3. Milestone Scientific Acquires Additional Patent Rights for Painless Injections and Resolves Related Litigations
4. MediCult Acquires US-Based MidAtlantic Diagnostics to Further Strengthen ART Presence
5. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
6. Safecor Health Acquires Unit-Dose Pharmaceutical Leader RSC
7. Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice
8. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
9. BioEnergy International, LLC Acquires Assets of OmniGene Bioproducts, Inc.
10. MacroGenics Acquires Raven Biotechnologies
11. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017 UCHealth ( Aurora, ... LungDirect for pulmonary nodule patient management. In addition to ... a spot on the lung, UCHealth looks to improve ... data entry. Stephanie Brown, RN , ... nodule patients with an Excel spreadsheet, which was extremely ...
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... Feb. 16, 2017  Windtree Therapeutics, Inc. (Nasdaq: ... on developing aerosolized KL4 surfactant therapies for respiratory ... influenza study showed that aerosolized KL4 surfactant reduced ... well-established preclinical animal model. The Company believes that ... of evidence that supports the role of KL4 ...
(Date:2/16/2017)... PHOENIX and NEW YORK ... announced the near completion of their $7M Series B ... on top of the $3.5M led by Mesa Verde ... of 2016.  These resources will be directed towards further ... Test, PCDx, a comprehensive genomic profiling test and expanding ...
Breaking Biology Technology:
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
Breaking Biology News(10 mins):